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Abstract
Background: Malignant peripheral nerve sheath tumours (MPNST) are known to develop in
patients with Neurofibromatosis type I (NF1) resulting in a decreased overall survival. The
association between NF1 and the development of such MPNST has been investigated in detail. The
biological behaviour however of multiple disseminated neurofibromas in patients with NF1 and the
risk factors for malignant transformation remain unknown. Clinical signs are unreliable and
additional imaging techniques are therefore required. Of such, positron emission tomography using
[18F]-2-fluoro-2-deoxy-D-glucose (18FDG PET) is used to detect malignant changes in
neurofibromas.
Case presentation: A case is presented of a patient suffering from NF1 with clinical signs of
malignant change and accumulation of 18FDG in multiple neurofibromas. Histopathological
examination of 20 lesions however, did not reveal any malignant features. There was no statistically
significant relation between18FDG accumulation and malignant change, but rather with pain, size
and growth.
Conclusion: This case adds to the knowledge of the diverse biological behaviour of neurofibromas
in patients with NF1
Background
Neurofibromatosis type I (NF1) is an autosomal domi-
nant multisystem disorder with an incidence of approxi-
mately 1 in every 3500 births [1-3]. The classical features
of NF1 are café au lait spots, neurofibromas, iris Lisch nod-
ules and skin fold freckling [3,4]. The neurofibromas arise
from peripheral nerve branches or sheaths of peripheral
nerve fibers and are derived from Schwann cells or
pluripotent cells of neural crest origin [5]. The lesions can
occur at virtually any site in the body and are generally
divided in nodular plexiform, diffuse plexiform, subcuta-
neous and cutaneous types (14). Patients with NF1 have a
decreased overall survival due to the development of
malignant peripheral nerve sheath tumours (MPNST).
MPNST arise from plexiform neurofibromas in approxi-
mately 10% of the patients [3,3,5-7]. MPNST may metas-
Published: 12 November 2007
World Journal of Surgical Oncology 2007, 5:130 doi:10.1186/1477-7819-5-130
Received: 8 June 2007
Accepted: 12 November 2007
This article is available from: http://www.wjso.com/content/5/1/130
© 2007 Brinkman et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.World Journal of Surgical Oncology 2007, 5:130 http://www.wjso.com/content/5/1/130
Page 2 of 7
(page number not for citation purposes)
tasize widely and are therefore associated with a poor
prognosis.
Diagnosis of a MPNST in patients with NF1 is based on
clinical, radiological and histological investigation. Rapid
growth, pain and neurological impairment are symptoms
associated with malignant transformation, however, the
symptoms are not specific and may also occur in benign
lesions [5,6]. Magnetic Resonance Imaging (MRI) accu-
rately reveals the site and extent of the lesion, but cannot
differentiate between benign and malignant lesions [8,9].
Histopathological examination of biopsy material is nec-
essary, but even this is not always conclusive since the
retrieved specimens may not represent the overall charac-
teristics of the tumour. Areas of high-grade activity
between larger areas of benign cells may be missed due to
sampling error [10]. Therefore, various radionuclide
imaging techniques have been described to detect the
development of MPNST in patients with NF1 [3,11,12].
Because sarcomas have high glucose metabolic rates
18fluorodeoxyglucose (18FDG) positron emission tomog-
raphy (PET) scanning is well established [1,4-6,13].
The presented case describes the correlation between clin-
ical, radiological, FDG-PET scanning and histopathologi-
cal findings in a patient with NF1, clinically suspected of
developing MPNST.
Case presentation
A 39-year old woman, known with NF1 and Sickle cell
anaemia, was referred to our hospital with complaints of
pain and notable growth of multiple neurofibromas
(Table 1). At examination, the patient had multiple cuta-
neously and subcutaneously located neurofibromas, most
notably at the following locations: left ankle, left lower
leg, right upper leg, right buttock (two) and right hip, var-
ying in size from four to eight centimetres (Table 1). MRI
studies of the suspected area's showed well-defined, cir-
cumscribed lesions having a homogenous aspect without
signs of invasion of surrounding structures. The signal
intensity was low on T1, moderate on T2 and high on
STIR. Thus, the MRI-studies were consistent with multiple,
complete benign appearing neurofibromas. 18FDG PET-
scanning however, showed multiple sites of increased
18FDG accumulation (Figure 1A and 1B). The correspond-
ing lesions were clearly detectable on the MRI-studies and
palpable on clinical examination. Therefore, ten neurofi-
bromas were selected for surgical resection (I-X, Table 1),
including four lesions with increased 18FDG accumula-
tion. Seven months post-operative, 18FDG PET-studies
showed no increased 18FDG accumulation in new areas,
nor in the neurofibromas left in situ, nor at the sites of
resected neurofibroma. One year postoperative however,
the patient started to complain about pain and discomfort
from neurofibromas that previously had been asympto-
Table 1: Details for each neurofibroma resected at the first and second operation
Neurofibroma Location Type Pain Growth Size (cm) FDG score Amount Pseudo 
capsule
Glut-1 HK II
Operation 1 I R buttock NP + + 2 + 4 - - ++
II R buttock 2 SC + + 4 + 3 + - +
III R flank SC - - 4 - 1 + - +
IV Abdomen NP - - 1.5 - 1 - - +
VL  u p p e r  a r m C - - 1 - 1 - - + +
VI Pubic area C - - 1 - 1 - - ++
VII L calf C + - 1 + 3 - - +
VIII R lower leg DP - - 1.5 - 1 - - ++
IX L ankle SC + + 4 + 4 + - +
X L knee SC - - 1 - 1 - - -
Operation 2 I Sternum DP - - 1.5 - 1 - - +
II R wrist rad SC - - 4 - 1 - - +++
III R wrist uln NP + + 5 + 3 + - ++
IV L breast DP - - 2.5 - 1 - - +
V R upper leg SC - - 6 + 3 + - +++
VI L wrist prox C - - 3 + 4 - - -
VII L wrist dist C - - 8 + 3 + - ++
VIII L arm pit SC - - 5 + 4 + - ++
IX R scapula SC + - 3 - 1 - - +
X Lower back C - - 1 - 1 - - +++
R = right, L = left, NP = nodular plexiform, SC = subcutaneous, C = cutaneous, DP = diffuse plexiform, Pain: + = pain, – = no pain, Growth: + = 
growth, – = no growth, Size: size on MRI in centimetres (cm) FDG uptake: + = accumulation of 18FDG on PET scanning, – = no uptake, Amount 
(see text): semi quantitative measurement of 18FDG uptake, Pseudo C: + formation of a pseudo capsule, – = no capsule, Glut-1: + = expression of 
Glut-1, – = no expression, HKII: + = semi quantitative measurement of HKII expression, – = no expression.World Journal of Surgical Oncology 2007, 5:130 http://www.wjso.com/content/5/1/130
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matic (XI-XX, Table 1). On clinical examination most
notable locations were: dorsal side of the left and right
wrist, right scapula and left shoulder (previously docu-
mented), varying in size on palpation from two to eight
centimetres. 18FDG PET was performed revealing multiple
new as well as previously documented sites of increased
18FDG accumulation (Figure 2, Table 1). Again, ten neu-
rofibromas (XI-XX) are selected for surgical resection. The
surgical interventions were both uneventful.
FDG PET scan
The PET-studies were performed using an ECAT EXACT
HR+ scanner (Siemens/CTI) after injection of 370 MBq of
[18F]-2-fluoro-2-deoxy-D-glucose (18FDG) and 2D-images
are obtained 60 minutes after injection. All scans were
corrected for decay, scatter and randoms and were recon-
structed using ordered subset expectation maximization
(OSEM) with 2 iterations and 16 subsets followed by post
smoothing of the reconstructed images using a 5 mm
FWHM Gaussian filter. No attenuation correction was
applied. Visual analysis of the PET scans was performed
with regard to size and intensity of 18FDG accumulation,
using a 4-point scale; 1: no uptake, 2: sparse uptake, 3:
moderate uptake, and 4: high uptake.
Histology and immunohistochemistry
In total, twenty neurofibromas were resected during the
two separate surgical interventions (ten each) and the
specimens (figure 3) were analyzed both, histopathologi-
cally and immunohistochemically. All specimens were
fixed in neutral 4% buffered formaldehyde for at least 24
hours. Immunohistochemical analysis was performed on
4 µm thick tissue sections. After deparaffination and rehy-
dration, endogenous peroxidase activity was blocked.
After antigen retrieval, a cooling-off period preceeds the
incubation of the antibodies for the glucose transporter
protein (Glut-1; DAKO, Glostrup, Denmark) and hexoki-
nase II (HK II; Chemicon, UK). Specific binding was
detected with a biotinylated swine-anti-rabbit-antibody
(DAKO) and an avidin-biotin complex (DAKO). Staining
was developed with diamminobenzidine and counter-
stained with haematoxylin/eosin. Intensity of staining
was categorized as negative (-), weak (+), positive (++)
and strongly positive (+++). Negative (obtained by omis-
sion of the primary antibody) and positive controls were
used throughout. For Glut-1 staining an internal control
was staining of erythrocytes (positive for glucosetrans-
porter-1).
Statistics
Statistical analysis of correlation between complaints
(pain and growth), size, tumour type, semi-quantitative
measurement of 18FDG accumulation and morphologic
(pseudo capsule formation) and immunohistochemical
characteristics (Glut 1 and HK II expression) was per-
formed using Spearman's Rank Correlation Coefficient.
SPSS software (Release v12.0, SPSS Inc, Chicago, Ill, USA)
was used for the statistical analyses. P-values < 0.05 were
designated significant.
Results
Macroscopically, the specimens of both surgical interven-
tions show features of completely benign neurofibromas.
All specimens show well defined, circumscribed neurofi-
broma without signs of macroscopic invasion of sur-
rounding structures (Figure 3). Microscopically, all
neurofibromas show the same morphological characteris-
tics including spindle cell proliferations with small, elon-
Magnetic resonance imaging A) Transaxial MRI scan (STIR, 5 mm slice thickness, left) B) Corresponding 18FDG PET scan (5 mm  slice thickness, right) Figure 1
Magnetic resonance imaging A) Transaxial MRI scan (STIR, 5 mm slice thickness, left) B) Corresponding 18FDG PET scan (5 mm 
slice thickness, right). Increased FDG uptake is seen in a subcutaneous lesion in the left shoulder region (arrow).World Journal of Surgical Oncology 2007, 5:130 http://www.wjso.com/content/5/1/130
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gated, hyperchromatic nuclei. In neurofibromas II, III, IX,
XIII, XIV, XVII and XVIII a slightly more expansive growth
pattern can be observed with increased cellularity and for-
mation of a pseudo-capsule. The surrounding pseudo cap-
sule is in fact the perineurium and indicates an origin of
the neurofibroma within a nerve. From the examined
lesions, 6 were plexiform neurofibroma's and the remain-
der of the lesions were either cutaneous or subcutaneous
according to Riccardi [14]. Although there is a slight vari-
ation in cellularity between different fibromas, no nuclear
atypia and no mitosis are seen.
Immunohistochemically, tumor cells stain all positive for
HK II with varying intensity, sporadically positive for Ki67
and negative for Glut-1 (Table 1, Figure 4). Expression of
Glut-1 is regulated by oncogenes and growth factors, and
causes increased activity of glycolytic enzymes [13,15].
Histopathological diagnosis of all 20 resected tumours
results in neurofibroma without signs of malignant trans-
A well defined, circumscribed neurofibroma, without signs of macroscopic invasion of surrounding structures, located on the  patients right upper leg, which showed 18FDG accumulation on PET scanning Figure 3
A well defined, circumscribed neurofibroma, without signs of macroscopic invasion of surrounding structures, located on the 
patients right upper leg, which showed 18FDG accumulation on PET scanning.
A) Transaxial MRI scan (STIR, 5 mm slice thickness, left) and B) Corresponding FDG-PET scan (5 mm slice thickness, right) Figure 2
A) Transaxial MRI scan (STIR, 5 mm slice thickness, left) and B) Corresponding FDG-PET scan (5 mm slice thickness, right). 
Increased FDG uptake is visible in a subcutaneous lesion located medially in the right upper leg (arrow).World Journal of Surgical Oncology 2007, 5:130 http://www.wjso.com/content/5/1/130
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formation. Six neurofibromas with increased 18FDG accu-
mulation show more expansive growth accompanied with
the formation of a pseudo capsule in three lesions (Table
1). One neurofibroma without 18FDG accumulation
shows the formation of a pseudo capsule, whereas 3 neu-
rofibromas with accumulation of 18FDG lack a pseudo
capsule (Table 1). There is a statistically significant corre-
lation between; pain and growth (p < 0.01), size and the
formation of a pseudo capsule (p < 0.01), and between
pain, growth and size and 18FDG accumulation (p <
0.05).
Discussion
MPNST account for 10% of all soft tissue sarcomas with
half of these malignancies arising in patients with NF1
[16]. The overall prognosis of MPNST is poor, with a 5-
year survival rate of only 20 % [4,17,18]. NF1 patients
have a higher incidence of MPNST at an early age
[2,19,20]. There is a peak incidence between 25 and 30
years of age, compared to between 40 and 60 years for
MPNST without NF1 [2,16,17]. In the present study, the
patient was diagnosed with neurofibromatosis and had
clinical signs suspected for malignant transformation. In
addition, accumulation of 18FDG was seen on PET scan-
ning in multiple neurofibromas. We showed that neither
clinical suspicion on MPNST, nor the presence of 18FDG
accumulation, nor both features combined are certain
parameters for malignancy. Histopathologic analysis of
20 neurofibromas divided over two separate occasions
revealed completely benign lesions. Immunohistochemi-
cal analysis showed hexokinase expression in all resected
lesions. Previous reports have documented 18FDG accu-
mulation in histopathologically benign neurofibromas
[1,21]. In this case however, all neurofibromas with
18FDG accumulation turned out to be benign. To our
knowledge this has not been documented previously. Sta-
tistically, pain and growth, size, the formation of a pseudo
capsule, and 18FDG accumulation were associated. There
Histological and Immunohistochemical analysis of the same neurofibroma Figure 4
Histological and Immunohistochemical analysis of the same neurofibroma. A) overview of the tumour stained with haematoxy-
lin (magnification 100×); B) positive control for HK II (staining of a cervical carcinoma section); C) negative control for Glut-1 
and HK II; D) Glut-1 staining (negative) with positively stained erythrocytes (internal positive control); E) HK II staining (posi-
tive) (B-E: magnification 400×)World Journal of Surgical Oncology 2007, 5:130 http://www.wjso.com/content/5/1/130
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was no statistically significant association between 18FDG
accumulation and tumour type or the intensity of hexoki-
nase expression.
Pain associated with a mass, and the presence of either
subcutaneous or cutaneous neurofibromas, has been
reported by King et al., [2] to be the greatest risk factor for
MPNST in patients with NF1. The presence of either sub-
cutaneous or cutaneous neurofibromas is of limited value
however, because of their high incidence in NF1 patients.
Furthermore, these investigators reported on 8 patients
with MPNST without pre-existing clinically detectable
plexiform neurofibroma [2]. Ducatman et al., [17]
reported 81% of MPNST to be associated with pre-existing
neurofibromatous tissue on pathological examination.
Both findings suggest that patients who lack clinically
detectable or symptomatic neurofibroma are not exempt
from the development of an MPNST.
Radionuclide imaging has been used to detect sarcoma-
tous changes in neurofibroma. Lee et al., [3] reported
increased Ga-67, Th-201 and Tc-99 m (V) DMSA uptake
in a MPNST (or neurofibrosarcoma) but not in benign
neurofibromas present in the same patient. Solomon et
al., [6] reported on a single mass in a patient with
increased glucose metabolism seen on a pre-operative PET
scan, corresponding with malignant transformation of a
neurofibroma at pathological examination. Ferner et al.,
[1] performed a qualitative and quantitative assessment of
18FDG accumulation in 18 patients with a known history
of NF1 with a clinical suspicion of malignant transforma-
tion of neurofibroma. In ten patients, histological confir-
mation was obtained of the suspected lesions based on
18FDG PET. No false negatives and two false positives were
reported and it was concluded that 18FDG PET could be a
useful method of identifying malignant change in neu-
rofibroma in NF1 patients. Cardona et al., [4] evaluated
the nature of 25 neurogenic tumours suspected of malig-
nancy, in patients with NF1, using 18FDG PET. Three-
dimensional qualitative and quantitative assessment of
FDG-PET scanning was compared to histological reports;
no histopathologically malignant tumours were classified
benign, but three benign tumours had been rated malig-
nant. Standard uptake value (SUV) was compared to his-
topathological diagnosis; the SUV was significantly higher
in MPNST at a cut off-value of 1.8 SUV. Cordana et al., rec-
ommended the use of 18FDG PET scanning in the follow-
up of patients with NF1 and that those lesions with a SUV
of 1.8 or more should be resected. Recently, Brenner et al.,
showed FDG PET scanning to be a stronger parameter for
the prediction of survival in patients with MPNST than
histopathological grading [22].
Malignant cells have an increased glucose uptake and
metabolism demonstrated both in vitro and in vivo [15]. In
various cancers, such as tumours of the oesophagus,
colon, pancreas, stomach, brain and breast, the major glu-
cose transporters protein (Glut-1) has been reported to be
up regulated [13,15]. To our knowledge this has not been
investigated in neurofibrosarcoma. Hexokinase is the first
glycolytic enzyme to phosphorylate glucose and FDG
intracellularly [13,15]. Increased expression of hexoki-
nases in breast and lung cancer has been described, but
not in other tumours [13]. In the current case immunohis-
tochemical analysis was performed for the presence of
Glut-1 and hexokinase expression; there was no Glut-1
expression and expression of hexokinase varied in inten-
sity. Hence, no association could be found between the
immunohistochemical results and the 18FDG PET scans.
Conclusion
We conclude that in this case there was no correlation
between 18FDG accumulation and malignancy, but rather
with pain, size and growth of the neurofibromas. The
findings in this patient with neurofibomatosis do not sup-
port the use of FDG PET in the setting of screening for
malignant transformation. However, FDG PET may be a
useful tool to rule out malignancy in patients with a clin-
ical suspicion for malignant transformation in lesions that
are difficult for surgical biopsy. This case adds to the
knowledge of the diverse biological behaviour of neurofi-
bromas in patients with NF1.
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